Name | hyperforin |
---|---|
Synonyms |
(1R,5S,6R,7S)-4-Hydroxy-6-methyl-1,3,7-tris(3-methyl-2-butenyl)-5-(2-methyl-1-oxopropyl)-6-(4-methyl-3-pentenyl)bicyclo[3.3.1]non-3-ene-2,9-dione
(1R,5S,6R,7S)-4-hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione Hyperforin (1R,5S,6R,7S)-4-Hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methylbut-2-en-1-yl)-6-(4-methylpent-3-en-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione (1R,5S,6R,7S)-4-Hydroxy-6-methyl-1,3,7-tris(3-methylbut-2-enyl)-6-(4-methylpent-3-enyl)-5-(2-methylpropanoyl)bicyclo[3.3.1]non-3-ene-2,9-dione Bicyclo[3.3.1]non-3-ene-2,9-dione, 4-hydroxy-6-methyl-1,3,7-tris(3-methyl-2-buten-1-yl)-5-(2-methyl-1-oxopropyl)-6-(4-methyl-3-penten-1-yl)-, (1R,5S,6R,7S)- MFCD01861497 (1R,5S,6R,7S)-4-Hydroxy-5-isobutyryl-6-methyl-1,3,7-tris(3-methyl-2-buten-1-yl)-6-(4-methyl-3-penten-1-yl)bicyclo[3.3.1]non-3-ene-2,9-dione |
Description | Hyperforin is a transient receptor canonical 6 (TRPC6) channels activator. Hyperforin modulates Ca2+ levels by activating Ca2+-conducting non-selective canonical TRPC6 channels. Hyperforin also shows diverse pharmacological activities including anti-depression, anti-tumor, anti-dementia, anti-diabetes. Hyperforin modulates γδ T cells to secret IL-17α, improves Imiquimod (HY-B0180)-induced psoriasis-like mice model[1][2][3][4][5]. |
---|---|
Related Catalog | |
Target |
TRPC6[1] |
In Vitro | Hyperforin 具有多向作用机制。它阻断配体门控 (GABA、NMDA 和 AMPA 受体) 和电压门控通道(Ca2+, K+, Na+) 的电导[2]。 Hyperforin (0.1, 1,10 μM; 2 h) 降低体外培养的小鼠脾 γδ T 细胞中 IL-17A 的表达和分泌[3]。 Hyperforin (0.1, 1,10 μM; 2 h) 抑制 TNF-α 刺激的 HaCaT 细胞中 MAPK 和 STAT3 通路的磷酸化[3]。 Hyperforin (IC50=3.7 μmol/L) 抑制 HDMEC 微血管管的形成和增殖,呈剂量依赖性,无毒性作用[4]。 Western Blot Analysis[3] Cell Line: HaCaT cells Concentration: 0.1, 1, 10 μM; with or without 10, 20 ng/mL TNF-α Incubation Time: 2 hours Result: Reduced the expressions of p-p38, p-ERK, p-JNK, and p-STAT3, especially at the dosage of 10 μM. |
In Vivo | Hyperforin (5 mg/kg; 腹腔注射; 每天 1 次, 共 7 天) 能够改善 Imiquimod (HY-B0180) 诱导的小鼠银屑病皮损情况,抑制炎症细胞浸润和炎症因子释放[3]。 Animal Model: IMQ-induced psoriasis-like mice model[3] Dosage: 5 mg/kg Administration: Intraperitoneal injection; once daily for 7 days Result: Significantly ameliorated skin lesion throughout the treatment period, demonstrated by the reduced severity score of skin inflammation. Suppressed infiltration of CD3+ T cells and downregulated expression of Il1, Il6, Il23, Il17a, Il22, antimicrobial peptides (AMPs) in the skin lesion. |
References |
Density | 1.0±0.1 g/cm3 |
---|---|
Boiling Point | 616.8±55.0 °C at 760 mmHg |
Melting Point | 79-80ºC |
Molecular Formula | C35H52O4 |
Molecular Weight | 536.785 |
Flash Point | 340.9±28.0 °C |
Exact Mass | 536.386536 |
PSA | 71.44000 |
LogP | 12.30 |
Vapour Pressure | 0.0±4.0 mmHg at 25°C |
Index of Refraction | 1.518 |
Symbol |
GHS02, GHS06, GHS08 |
---|---|
Signal Word | Danger |
Hazard Statements | H225-H301 + H311 + H331-H370 |
Precautionary Statements | P210-P280-P302 + P352 + P312-P304 + P340 + P312-P370 + P378-P403 + P235 |
Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
Hazard Codes | F,T |
Risk Phrases | 11-23/24/25-39/23/24/25 |
Safety Phrases | 7-16-36/37-45 |
RIDADR | UN1230 - class 3 - PG 2 - Methanol |
WGK Germany | 3 |
HS Code | 29144000 |